灵康药业(603669) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months increased by 2.50% to CNY 1,211,402,545.61 compared to the same period last year[6] - Net profit attributable to shareholders decreased by 9.28% to CNY 150,716,017.31 compared to the same period last year[6] - Basic earnings per share decreased by 9.09% to CNY 0.30 compared to the same period last year[7] - The weighted average return on net assets decreased by 1.14 percentage points to 11.29% compared to the same period last year[7] - Total operating revenue for Q3 2019 was CNY 374,341,024.34, a 2.93% increase from CNY 365,278,953.16 in Q3 2018[25] - Net profit for Q3 2019 was CNY 41,217,193.96, a decrease of 57.5% compared to CNY 96,974,398.26 in Q3 2018[27] - Total comprehensive income for Q3 2019 was CNY 41,217,193.96, compared to CNY 96,974,398.26 in Q3 2018, reflecting a decrease of 57.5%[28] - The company reported a total profit of CNY 46,589,257.65 for Q3 2019, down from CNY 106,784,528.04 in Q3 2018, a decline of 56.4%[26] Assets and Liabilities - Total assets increased by 1.88% to CNY 2,106,743,588.79 compared to the end of the previous year[6] - Total liabilities reached CNY 843,788,471.61, compared to CNY 689,967,645.91, marking an increase of approximately 22.3%[19] - Current liabilities rose to CNY 659,932,995.48, up from CNY 504,372,424.75, indicating a significant increase of about 30.8%[19] - Total assets as of Q3 2019 were CNY 1,980,075,467.62, down from CNY 2,070,101,417.57 in the previous year, indicating a decline of 4.35%[23] - Total liabilities as of Q3 2019 amounted to CNY 656,972,080.38, an increase from CNY 639,305,610.15 in the previous year[23] - Total equity decreased to CNY 1,323,103,387.24 in Q3 2019 from CNY 1,430,795,807.42 in Q3 2018, representing a decline of 7.5%[23] Cash Flow - Net cash flow from operating activities increased by 15.84% to CNY 165,562,692.12 compared to the same period last year[6] - Cash inflow from operating activities for the first three quarters of 2019 was RMB 1,381,840,197.15, down from RMB 1,491,125,400.80 in the same period of 2018, reflecting a decrease of approximately 7.4%[34] - Cash outflow for operating activities totaled 1,454,693,186.14 RMB, compared to 1,320,986,223.52 RMB in the previous year, indicating an increase of approximately 10.1%[37] - The net cash flow from investment activities was -224,901,756.59 RMB, worsening from -62,817,296.00 RMB in the same period last year[36] - Cash inflow from investment activities was 928,152,601.33 RMB, significantly higher than 628,693,028.85 RMB in the previous year, representing an increase of about 47.7%[36] - The net cash flow from financing activities was -121,400,166.71 RMB, compared to -9,886,111.12 RMB in the same period of 2018[38] Shareholder Information - The total number of shareholders reached 21,580 at the end of the reporting period[12] - The largest shareholder, Lingkang Holdings Group Co., Ltd., holds 49.50% of the shares and has pledged 196,531,200 shares[12] Research and Development - R&D expenses increased by 195.26% to ¥34,989,550 from ¥11,850,427 due to the completion of previously prepaid R&D projects[14] - Research and development expenses for Q3 2019 were CNY 2,337,235.00, significantly lower than CNY 4,468,247.44 in Q3 2018, indicating a 47.7% reduction[26] - Research and development expenses for the first three quarters of 2019 totaled RMB 10,095,000.00, with no R&D expenses reported in the same period of 2018[30] Financial Position - Owner's equity attributable to shareholders decreased to CNY 1,262,955,117.18 from CNY 1,377,959,099.87, a decline of about 8.3%[20] - The company reported a total non-current asset value of CNY 729,186,272.11, slightly down from CNY 741,464,789.81, a decrease of about 1.6%[20] - The company reported a cash and cash equivalents net decrease of 180,739,231.18 RMB for the third quarter of 2019[36] - The company has long-term investments amounting to CNY 92,224,705.58 in long-term equity investments[40] Government Subsidies and Financial Standards - The company reported a government subsidy of CNY 38,807,563.96 during the reporting period[8] - The company implemented new financial instrument standards effective January 1, 2019, with no significant impact on financial results[42] - The company has not reported any retrospective adjustments for prior comparative data[47]